Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 11, 2022

SELL
$4.75 - $7.5 $270 - $427
-57 Closed
0 $0
Q3 2021

Nov 10, 2021

SELL
$5.02 - $6.59 $527 - $691
-105 Reduced 64.81%
57 $0
Q2 2021

Aug 11, 2021

BUY
$5.79 - $8.6 $937 - $1,393
162 New
162 $1,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Zions Bancorporation, N.A. Portfolio

Follow Zions Bancorporation, N.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zions Bancorporation, N.A., based on Form 13F filings with the SEC.

News

Stay updated on Zions Bancorporation, N.A. with notifications on news.